Trial Profile
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Granulomatosis with polyangiitis
- Focus Therapeutic Use
- Acronyms RENTGPA
- 20 Mar 2018 Status changed from recruiting to discontinued.
- 20 Apr 2017 Status changed from not yet recruiting to recruiting.
- 11 Dec 2015 New trial record